Bradley Prechtl, MBA, chief executive officer of Florida Cancer Specialists and the American Oncology Network discusses how Florida Cancer Specialists is working with employers.
Bradley Prechtl, MBA, chief executive officer of Florida Cancer Specialists and the American Oncology Network discusses how Florida Cancer Specialists is working with employers.
Transcript
With employers playing a more active role in the health of their employees, how is Florida Cancer Specialists working with employers?
We’re partnering with employers. I think the goal is to really, in many parts of the country and Florida is not different, we’re trying to go directly to the employers and have partnerships and work and have open lines of communication about what’s happening within the cancer community and equally important what’s happening within their base of employees and covered dependents.
Cancer’s typically going to be one of the top 2 or 3 highest expenses that an employer will incur related to the care of their employee base and their covered dependents. So, we’ve been, for the last couple of years, partnering with these large employers trying to number 1 make sure there’s good access to care, number 2 improving quality, and equally important, lowering expenses.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More